Michael Pape

Esperion Theraputics

Dr. Pape is President and CEO of Nymirum and a Founding Partner of Sigvion Capital, a life-science venture capital firm.  Dr. Pape has worked in both large pharmaceutical companies and startup life science companies. At Upjohn and Parke-Davis/Warner-Lambert (now Pfizer) he was instrumental in the success of numerous cardiovascular drug discovery and development programs including Lipitor and other novel drugs. He has published dozens of articles detailing the biochemistry that underlies atherosclerosis, diabetes, and obesity. Dr. Pape left Pfizer in 1998 to co-found Esperion Therapeutics, a biopharmaceutical company focused on developing novel cardiovascular therapeutics. He was involved in nearly all aspects of building Esperion, from its startup to its acquisition by Pfizer for $1.3 billion in 2004.

Dr. Pape is co-founder of Esperion Therapeutics, Akebia Therapeutics, Nymirum, and Sigvion Capital.

Dr. Pape received his bachelor’s degree in Microbiology from the University of Michigan, Ph.D. in Biochemistry from Purdue University, and MBA from the University of Chicago, Booth School of Business.